Go Pro
→ Pass by August 7… or wait until 2027? (From Crypto 101 Media) (Ad)tc pixel Free ROIV Stock Alerts

Roivant Sciences (ROIV) Financials

Roivant Sciences logo
$37.11 -0.29 (-0.78%)
As of 11:51 AM Eastern
Compare
Annual Income Statements for Roivant Sciences

Annual Income Statements for Roivant Sciences

This table shows Roivant Sciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 3/31/2021 3/31/2022 3/31/2023 3/31/2024 3/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -809 -845 -1,009 4,349 -172 -300
Consolidated Net Income / (Loss)		 -900 -924 -1,115 4,231 -357 -398
Net Income / (Loss) Continuing Operations		 -900 -924 -889 4,546 -730 -398
Total Pre-Tax Income 		-899 -924 -885 4,568 -682 -265
Total Operating Income		 -1,071 -1,352 -907 4,497 -1,003 -515
Total Gross Profit		 24 55 32 33 29 8.26
Total Revenue		 24 55 32 33 29 8.26
Operating Revenue		 24 55 32 33 29 8.26
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 1,095 1,407 938 -4,464 1,032 523
Selling, General & Admin Expense		 260 775 383 416 591 610
Research & Development Expense		 833 623 552 466 550 682
Other Operating Expenses / (Income)		 2.06 8.97 3.03 1.60 0.91 1.29
Other Special Charges / (Income)		 - - 0.00 -5,348 -110 -770
Total Other Income / (Expense), net		 172 428 22 71 322 250
Interest & Investment Income		 211 362 41 131 317 294
Other Income / (Expense), net		 -39 73 -19 -60 5.04 -44
Income Tax Expense		 1.69 0.37 4.08 22 48 133
Net Income / (Loss) Discontinued Operations		 - 0.00 -226 -315 373 0.00
Net Income / (Loss) Attributable to Noncontrolling Interest		 -91 -79 -106 -118 -185 -98
Basic Earnings per Share		 ($1.28) ($1.26) ($1.42) $5.55 ($0.24) ($0.43)
Weighted Average Basic Shares Outstanding		 630.05M 669.75M 712.79M 783.25M 725.40M 693.86M
Diluted Earnings per Share		 ($1.28) ($1.26) ($1.42) $5.23 ($0.24) ($0.54)
Weighted Average Diluted Shares Outstanding		 630.05M 669.75M 712.79M 831.05M 725.40M 693.86M
Weighted Average Basic & Diluted Shares Outstanding		 630.05M 669.75M 669.75M 738.72M 679.81M 719.27M

Quarterly Income Statements for Roivant Sciences

This table shows Roivant Sciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 12/31/2023 3/31/2023 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 5,096 -5,509 95 -230 169 -206 -223 -114 -266 303 -190
Consolidated Net Income / (Loss)		 5,073 -5,529 57 -280 118 -252 -274 -166 -314 356 -291
Net Income / (Loss) Continuing Operations		 5,131 -5,789 -32 -237 -209 -341 -274 -166 -314 356 -291
Total Pre-Tax Income 		5,154 -5,811 -20 -224 -235 -293 -269 -159 -290 454 -295
Total Operating Income		 5,127 -5,812 -102 -342 -274 -267 -285 -306 -339 415 -366
Total Gross Profit		 16 20 7.78 4.48 9.02 -40 2.17 1.57 2.00 2.67 1.44
Total Revenue		 16 20 7.99 4.48 9.02 -40 2.17 1.57 2.00 2.52 1.44
Operating Revenue		 16 20 7.99 4.48 9.02 -40 2.17 1.57 2.00 2.52 1.44
Total Cost of Revenue		 0.00 - 0.21 0.00 0.00 - 0.00 0.00 0.00 -0.15 0.00
Total Operating Expenses		 -5,112 5,833 110 346 283 227 287 308 341 -413 367
Selling, General & Admin Expense		 128 228 100 203 142 98 134 143 175 158 166
Research & Development Expense		 108 248 121 143 142 133 153 165 165 199 202
Other Operating Expenses / (Income)		 0.20 8.49 - 0.23 0.26 -3.56 0.15 0.11 0.70 - 0.28
Other Special Charges / (Income)		 -5,348 5,348 -110 0.00 0.00 - 0.00 0.00 0.00 -770 -0.39
Total Other Income / (Expense), net		 26 1.59 83 117 40 -26 16 147 49 39 71
Interest & Investment Income		 21 24 87 118 41 71 29 174 65 26 74
Other Income / (Expense), net		 4.60 -3.56 -4.76 -0.82 -0.67 -110 -14 -27 -16 13 -2.13
Income Tax Expense		 22 -22 12 12 -26 49 4.65 7.00 23 98 -3.96
Net Income / (Loss) Attributable to Noncontrolling Interest		 -24 -20 -38 -50 -51 -46 -51 -53 -48 53 -101
Basic Earnings per Share		 $6.37 ($7.01) $0.13 ($0.31) $0.23 ($0.29) ($0.33) ($0.17) ($0.38) $0.45 ($0.26)
Weighted Average Basic Shares Outstanding		 800.59M 712.79M 735.82M 735.47M 722.72M 725.40M 680.29M 680.95M 696.86M 693.86M 720.78M
Diluted Earnings per Share		 $6.03 ($6.67) $0.12 ($0.31) $0.23 ($0.28) ($0.33) ($0.17) ($0.38) $0.34 ($0.26)
Weighted Average Diluted Shares Outstanding		 844.46M 712.79M 781.63M 735.47M 722.72M 725.40M 680.29M 680.95M 696.86M 693.86M 720.78M
Weighted Average Basic & Diluted Shares Outstanding		 805.85M 738.72M 739.52M 727.95M 713.55M 679.81M - 695.49M 715.70M 719.27M 722.32M

Annual Cash Flow Statements for Roivant Sciences

This table details how cash moves in and out of Roivant Sciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 3/31/2021 3/31/2022 3/31/2023 3/31/2024 3/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -128 -68 -382 4,858 -3,826 -1,298
Net Cash From Operating Activities		 -552 -678 -843 -765 -839 -750
Net Cash From Continuing Operating Activities		 -552 -678 -843 -765 -839 -750
Net Income / (Loss) Continuing Operations		 -900 -924 -1,115 4,231 -357 -398
Consolidated Net Income / (Loss)		 -900 -924 -1,115 4,231 -357 -398
Depreciation Expense		 - 5.93 19 22 14 3.35
Amortization Expense		 - - 0.00 - -70 -37
Non-Cash Adjustments To Reconcile Net Income		 276 225 247 -5,038 -350 -468
Changes in Operating Assets and Liabilities, net		 72 16 6.35 19 -77 148
Net Cash From Investing Activities		 -32 303 -44 5,204 -1,766 -682
Net Cash From Continuing Investing Activities		 -32 303 -44 5,204 -1,766 -682
Purchase of Property, Plant & Equipment		 -5.81 -17 -13 -1.38 -4.60 -8.21
Acquisitions		 - -0.04 -6.71 -84 -31 -4.42
Purchase of Investments		 - - 0.00 0.00 -4,062 -4,796
Sale of Property, Plant & Equipment		 - - 0.00 5,233 110 0.00
Divestitures		 - - 0.00 48 261 0.00
Sale and/or Maturity of Investments		 0.00 320 0.00 0.00 1,960 4,129
Other Investing Activities, net		 -26 0.60 -25 8.59 0.08 -2.52
Net Cash From Financing Activities		 456 307 499 419 -1,220 134
Net Cash From Continuing Financing Activities		 456 307 499 419 -1,220 134
Repayment of Debt		 0.00 -23 -30 -31 -53 0.00
Repurchase of Common Equity		 - - 0.00 0.00 -1,293 -320
Payment of Dividends		 - - 0.00 -6.00 0.00 0.00
Issuance of Common Equity		 456 0.00 380 440 114 195
Other Financing Activities, net		 0.51 294 -10 17 12 259
Cash Interest Paid		 2.02 5.54 5.30 10 5.96 0.00

Quarterly Cash Flow Statements for Roivant Sciences

This table details how cash moves in and out of Roivant Sciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 12/31/2023 3/31/2023 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 5,262 -5,375 -857 -3,664 -27 724 -1,477 -1.45 242 -62 -245
Net Cash From Operating Activities		 -210 -187 -193 -267 -207 -173 -204 -186 -196 -164 -271
Net Cash From Continuing Operating Activities		 -210 -187 -193 -267 -207 -173 -275 -186 -196 -164 -345
Net Income / (Loss) Continuing Operations		 5,073 -5,529 57 -280 118 -252 -274 -166 -314 356 -291
Consolidated Net Income / (Loss)		 5,073 -5,529 57 -280 118 -252 -274 -166 -314 356 -291
Depreciation Expense		 5.39 2.05 4.88 4.84 2.92 1.43 1.10 0.92 0.69 0.64 0.60
Amortization Expense		 - - 0.00 - -29 -16 -11 -9.82 -8.72 -6.91 -5.69
Non-Cash Adjustments To Reconcile Net Income		 -5,310 5,337 -186 23 -246 60 46 -18 116 -682 -18
Changes in Operating Assets and Liabilities, net		 21 3.27 -69 10 -53 34 -37 7.08 9.37 169 -31
Net Cash From Investing Activities		 5,233 -5,241 -0.97 -3,294 454 1,074 -1,086 120 109 173 281
Net Cash From Continuing Investing Activities		 5,233 -5,241 -0.97 -3,294 454 1,074 -1,086 120 109 173 281
Purchase of Property, Plant & Equipment		 -0.36 -12 -0.97 -1.00 -1.83 -0.81 -4.04 -7.85 4.94 -1.26 -0.42
Purchase of Investments		 - - 0.00 - -659 - -1,802 -977 -1,014 -1,004 -287
Sale and/or Maturity of Investments		 - - 0.00 - - 1,000 720 1,105 1,121 1,183 568
Net Cash From Financing Activities		 237 47 -661 -109 -273 -177 -188 63 328 -69 -182
Net Cash From Continuing Financing Activities		 237 47 -661 -109 -273 -177 -188 63 328 -69 -182
Repurchase of Common Equity		 - - -648 -106 -243 -295 -208 - - -111 -207
Issuance of Common Equity		 239 -59 - - - 113 0.00 - 194 - 0.64
Other Financing Activities, net		 5.57 -52 -10 -1.84 19 5.13 21 62 134 42 25

Annual Balance Sheets for Roivant Sciences

This table presents Roivant Sciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 3/31/2021 3/31/2022 3/31/2023 3/31/2024 3/31/2025 3/31/2026
Total Assets		 2,590 2,585 2,390 7,222 5,437 5,709
Total Current Assets		 2,187 2,147 1,799 6,732 5,000 5,167
Cash & Equivalents		 2,055 2,060 1,677 6,495 2,715 1,419
Short-Term Investments		 - - - 0.00 2,171 2,873
Other Current Assets		 54 86 122 81 113 876
Plant, Property, & Equipment, net		 15 26 39 15 12 12
Total Noncurrent Assets		 388 413 552 475 425 529
Long-Term Investments		 290 326 304 248 303 408
Other Noncurrent Operating Assets		 98 87 103 82 122 121
Total Liabilities & Shareholders' Equity		 2,590 2,585 2,390 7,222 5,437 5,709
Total Liabilities		 528 524 782 774 250 416
Total Current Liabilities		 219 184 272 267 149 281
Accounts Payable		 21 35 38 14 24 18
Accrued Expenses		 77 128 167 119 114 206
Current Deferred & Payable Income Tax Liabilities		 - - - - 0.42 46
Other Current Liabilities		 116 22 27 23 11 12
Total Noncurrent Liabilities		 309 339 510 507 100 135
Noncurrent Deferred & Payable Income Tax Liabilities		 - - - - 0.00 39
Other Noncurrent Operating Liabilities		 138 129 134 73 100 96
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 2,040 2,039 1,608 6,449 5,187 5,292
Total Preferred & Common Equity		 1,798 1,657 1,158 5,969 4,688 4,527
Total Common Equity		 1,798 1,657 1,158 5,969 4,688 4,527
Common Stock		 3,815 4,422 4,933 5,396 4,562 5,025
Retained Earnings		 -1,918 -2,764 -3,773 576 116 -502
Accumulated Other Comprehensive Income / (Loss)		 1.45 -0.95 -2.62 -4.08 9.44 4.36
Noncontrolling Interest		 242 382 450 480 500 765

Quarterly Balance Sheets for Roivant Sciences

This table presents Roivant Sciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 12/31/2022 6/30/2023 9/30/2023 12/31/2023 6/30/2024 9/30/2024 12/31/2024 6/30/2025 9/30/2025 12/31/2025 6/30/2026
Total Assets		 2,203 2,137 2,066 7,313 6,496 6,206 5,792 5,033 5,063 5,225 5,306
Total Current Assets		 1,646 1,561 1,552 6,807 6,001 5,801 5,364 4,616 4,512 4,660 4,742
Cash & Equivalents		 1,527 1,434 1,408 6,671 5,679 1,959 1,991 1,238 1,237 1,478 1,248
Short-Term Investments		 - - - - - 3,428 3,156 3,265 3,149 3,052 2,594
Other Current Assets		 119 127 143 136 323 94 217 113 126 130 900
Plant, Property, & Equipment, net		 37 36 24 22 18 14 14 15 26 13 11
Total Noncurrent Assets		 519 539 489 484 477 391 415 402 525 552 553
Long-Term Investments		 272 296 250 240 263 311 290 284 412 434 445
Other Noncurrent Operating Assets		 101 98 98 94 78 80 125 118 113 118 108
Total Liabilities & Shareholders' Equity		 2,203 2,137 2,066 7,313 6,496 6,206 5,792 5,033 5,063 5,225 5,306
Total Liabilities		 776 803 740 728 601 626 256 217 257 251 385
Total Current Liabilities		 244 245 266 245 215 556 141 114 134 152 284
Accounts Payable		 48 50 44 35 28 25 24 12 15 13 25
Accrued Expenses		 132 119 153 122 138 111 104 89 108 118 169
Current Deferred & Payable Income Tax Liabilities		 - - - - - - - - - - 74
Other Current Liabilities		 26 31 20 42 37 18 13 14 10 21 16
Total Noncurrent Liabilities		 532 558 474 483 386 70 115 103 123 99 101
Noncurrent Deferred & Payable Income Tax Liabilities		 - - - - - - - - - - 0.00
Other Noncurrent Operating Liabilities		 156 172 85 80 74 70 115 103 123 99 101
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 1,427 1,334 1,326 6,585 5,895 5,580 5,536 4,816 4,805 4,974 4,922
Total Preferred & Common Equity		 956 911 949 6,090 5,435 5,153 5,189 4,346 4,362 4,269 4,231
Total Common Equity		 956 911 949 6,090 5,435 5,153 5,189 4,346 4,362 4,269 4,231
Common Stock		 4,695 4,982 5,321 5,390 4,782 4,775 4,721 4,644 4,772 4,944 5,131
Retained Earnings		 -3,739 -4,065 -4,369 727 671 396 460 -316 -429 -695 -900
Accumulated Other Comprehensive Income / (Loss)		 -0.73 -6.61 -3.07 -28 -18 -18 8.06 17 20 21 0.70
Noncontrolling Interest		 472 423 377 495 460 427 346 470 443 705 691

Annual Metrics And Ratios for Roivant Sciences

This table displays calculated financial ratios and metrics derived from Roivant Sciences' official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 3/31/2021 3/31/2021 3/31/2022 3/31/2024 3/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - 715,701,137.00
DEI Adjusted Shares Outstanding		 - - - - - 715,701,137.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - -0.42
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 0.00% 132.34% 125.73% -11.19% -71.57%
EBITDA Growth		 0.00% 0.00% -14.71% 428.12% -123.64% 43.85%
EBIT Growth		 0.00% 0.00% -15.25% 425.13% -122.50% 44.03%
NOPAT Growth		 0.00% 0.00% -26.22% 546.00% -115.69% 48.66%
Net Income Growth		 0.00% 0.00% -2.65% 557.87% -108.43% -11.54%
EPS Growth		 0.00% 0.00% 1.56% 515.08% -104.59% -125.00%
Operating Cash Flow Growth		 0.00% 0.00% -22.75% -24.44% -9.69% 10.61%
Free Cash Flow Firm Growth		 0.00% 0.00% 0.00% 507.01% -117.03% -27.16%
Invested Capital Growth		 0.00% 0.00% 39.59% 54.72% 94.94% 22,614.97%
Revenue Q/Q Growth		 0.00% 0.00% 375.13% 6.44% -67.38% -37.94%
EBITDA Q/Q Growth		 0.00% 0.00% -19.17% -0.75% 83.59% 54.52%
EBIT Q/Q Growth		 0.00% 0.00% -19.73% -0.97% 84.49% 55.66%
NOPAT Q/Q Growth		 0.00% 0.00% -45.78% 3.50% 84.68% 57.62%
Net Income Q/Q Growth		 0.00% 0.00% 30.10% -6.89% 93.67% 60.45%
EPS Q/Q Growth		 0.00% 0.00% 30.39% -2.79% 96.38% 53.45%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 1.23% -25.84% 1.64% 1.15%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% -22.87% 4.07% 83.52% -25.49%
Invested Capital Q/Q Growth		 0.00% -33.67% -386.36% -142.29% -102.65% 5,631.64%
Profitability Metrics		 - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -4,662.51% -4,662.51% -2,301.93% 3,346.16% -3,628.36% -7,166.15%
Operating Margin		 -4,500.52% -4,500.52% -2,444.82% 3,399.19% -3,453.32% -6,235.69%
EBIT Margin		 -4,662.51% -4,662.51% -2,312.66% 3,331.05% -3,435.99% -6,764.65%
Profit (Net Income) Margin		 -3,783.29% -3,783.29% -1,671.52% 3,390.53% -1,227.87% -4,817.28%
Tax Burden Percent		 100.19% 100.19% 100.04% 99.48% 52.34% 150.39%
Interest Burden Percent		 80.99% 80.99% 72.25% 102.32% 68.28% 47.35%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.52% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% -122.23%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% -121.47%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 114.63%
Return on Equity (ROE)		 -43.66% -43.66% -44.82% 99.44% -6.13% -7.59%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% -161.29%
Operating Return on Assets (OROA)		 -42.84% -42.84% -49.42% 84.77% -15.77% -10.03%
Return on Assets (ROA)		 -34.76% -34.76% -35.72% 86.28% -5.64% -7.14%
Return on Common Equity (ROCE)		 -38.06% -38.06% -37.55% 89.11% -5.62% -6.68%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -50.07% -55.77% 70.89% -7.61% 0.00%
Net Operating Profit after Tax (NOPAT)		 -750 -750 -946 4,220 -702 -361
NOPAT Margin		 -3,150.36% -3,150.36% -1,711.37% 3,381.43% -2,417.33% -4,364.98%
Net Nonoperating Expense Percent (NNEP)		 -6.69% -6.69% 1.00% 0.26% 5.91% -0.76%
Return On Investment Capital (ROIC_SIMPLE)		 -33.92% - - - -13.54% -6.81%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 1,092.15% 1,092.15% 1,401.86% 550.86% 2,035.62% 7,390.63%
R&D to Revenue		 3,499.72% 3,499.72% 1,126.74% 423.24% 1,894.51% 8,254.38%
Operating Expenses to Revenue		 4,600.52% 4,600.52% 2,544.82% -3,299.19% 3,553.32% 6,335.69%
Earnings before Interest and Taxes (EBIT)		 -1,109 -1,109 -1,279 4,157 -998 -559
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -1,109 -1,109 -1,273 4,176 -1,054 -592
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 2.06 1.42 1.54 4.38
Price to Tangible Book Value (P/TBV)		 0.00 0.00 2.06 1.42 1.54 4.38
Price to Revenue (P/Rev)		 0.00 0.00 61.84 68.06 247.81 2,400.11
Price to Earnings (P/E)		 0.00 0.00 0.00 1.95 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 51.20% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 26.81
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 29.79 17.88 86.38 1,923.75
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.53 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.54 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.53 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.54 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.08 0.08 0.10 0.00 0.00 0.00
Long-Term Debt to Equity		 0.08 0.08 0.10 0.00 0.00 0.00
Financial Leverage		 -1.09 -1.09 -1.07 -1.02 -1.00 -0.94
Leverage Ratio		 1.26 1.26 1.26 1.15 1.09 1.06
Compound Leverage Factor		 1.02 1.02 0.91 1.18 0.74 0.50
Debt to Total Capital		 7.63% 7.63% 9.25% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 7.63% 7.63% 9.25% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 11.84% 11.84% 17.81% 7.44% 9.63% 14.46%
Common Equity to Total Capital		 80.54% 80.54% 72.95% 92.56% 90.37% 85.54%
Debt to EBITDA		 -0.15 -0.15 -0.17 0.00 0.00 0.00
Net Debt to EBITDA		 2.03 2.03 1.71 0.00 0.00 0.00
Long-Term Debt to EBITDA		 -0.15 -0.15 -0.17 0.00 0.00 0.00
Debt to NOPAT		 -0.23 -0.23 -0.22 0.00 0.00 0.00
Net Debt to NOPAT		 3.00 3.00 2.30 0.00 0.00 0.00
Long-Term Debt to NOPAT		 -0.23 -0.23 -0.22 0.00 0.00 0.00
Altman Z-Score		 0.00 0.00 1.72 9.69 17.80 29.16
Noncontrolling Interest Sharing Ratio		 12.81% 12.81% 16.22% 10.39% 8.42% 12.07%
Liquidity Ratios		 - - - - - -
Current Ratio		 9.99 9.99 11.64 25.24 33.47 18.37
Quick Ratio		 9.39 9.39 11.18 24.35 32.71 15.26
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 0.00 -1,021 4,157 -752 -956
Operating Cash Flow to CapEx		 -9,509.78% -9,509.78% -3,886.95% -6,646.12% 0.00% -9,140.57%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 -145.06 119.53 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 -96.25 -24.25 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 -98.73 -24.62 0.00 0.00
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.01 0.01 0.02 0.03 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 1.61 1.61 2.72 6.05 2.12 0.69
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 -190 -190 -115 -52 -2.63 593
Invested Capital Turnover		 -0.13 -0.13 -0.36 -1.50 -1.06 0.03
Increase / (Decrease) in Invested Capital		 0.00 0.00 75 63 49 595
Enterprise Value (EV)		 0.00 0.00 1,647 2,231 2,509 15,890
Market Capitalization		 0.00 0.00 3,419 8,494 7,200 19,825
Book Value per Share		 $2.85 $2.85 $2.39 $7.41 $6.57 $6.33
Tangible Book Value per Share		 $2.85 $2.85 $2.39 $7.41 $6.57 $6.33
Total Capital		 2,232 2,232 2,271 6,449 5,187 5,292
Total Debt		 170 170 210 0.00 0.00 0.00
Total Long-Term Debt		 170 170 210 0.00 0.00 0.00
Net Debt		 -2,252 -2,252 -2,176 -6,743 -5,190 -4,700
Capital Expenditures (CapEx)		 5.81 5.81 17 13 -106 8.21
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -165 -165 -98 -30 -36 594
Debt-free Net Working Capital (DFNWC)		 1,968 1,968 1,962 6,465 4,851 4,886
Net Working Capital (NWC)		 1,968 1,968 1,962 6,465 4,851 4,886
Net Nonoperating Expense (NNE)		 151 151 -22 -11 -346 37
Net Nonoperating Obligations (NNO)		 -2,252 -2,252 -2,176 -6,501 -5,190 -4,700
Total Depreciation and Amortization (D&A)		 0.00 0.00 5.93 19 -56 -33
Debt-free, Cash-free Net Working Capital to Revenue		 -692.21% -692.21% -177.70% -23.95% -124.73% 7,195.00%
Debt-free Net Working Capital to Revenue		 8,270.79% 8,270.79% 3,549.10% 5,180.55% 16,695.88% 59,154.24%
Net Working Capital to Revenue		 8,270.79% 8,270.79% 3,549.10% 5,180.55% 16,695.88% 59,154.24%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($1.26) $5.55 ($0.24) ($0.43)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 700.77M 783.25M 725.40M 693.86M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($1.26) $5.23 ($0.24) ($0.54)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 700.77M 831.05M 725.40M 693.86M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 ($1.26) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 669.75M 738.72M 679.81M 719.27M
Normalized Net Operating Profit after Tax (NOPAT)		 -750 -750 -946 -1,101 -780 -900
Normalized NOPAT Margin		 -3,150.36% -3,150.36% -1,711.37% -881.94% -2,683.29% -10,892.40%
Pre Tax Income Margin		 -3,776.20% -3,776.20% -1,670.85% 3,408.33% -2,346.02% -3,203.12%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 0.00 0.00 -181.59 119.53 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 -134.38 121.34 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 -184.07 119.16 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 -136.85 120.97 0.00 0.00
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% -362.52% -80.30%

Quarterly Metrics And Ratios for Roivant Sciences

This table displays calculated financial ratios and metrics derived from Roivant Sciences' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 12/31/2023 3/31/2023 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 - - - - - - - - - 715,701,137.00 719,270,385.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - 715,701,137.00 719,270,385.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - 0.42 -0.26
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -8.74% -4.38% 154.96% 22.67% -42.05% -387.28% -72.84% -64.89% -77.83% -66.71% -33.55%
EBITDA Growth		 1,331.44% -2,090.43% 100.34% -52.37% -105.87% -186.18% -202.05% 5.77% -20.53% 246.41% -21.01%
EBIT Growth		 1,315.14% -2,150.31% 98.83% -50.76% -105.36% -165.62% -178.95% 2.82% -29.15% 256.32% -23.34%
NOPAT Growth		 2,029.01% -825.75% 49.09% -59.76% -103.76% -90.56% -178.69% 10.38% -23.61% 263.08% -28.45%
Net Income Growth		 1,417.93% -4,337.40% 117.54% 15.46% -97.67% -38.29% -576.45% 40.68% -365.68% 240.96% -6.10%
EPS Growth		 1,330.61% 0.00% 131.58% 22.50% -96.19% -1,300.00% -375.00% 45.16% -265.22% 221.43% 21.21%
Operating Cash Flow Growth		 5.45% -1,289.91% 22.85% -35.83% 1.52% -59.11% -5.99% 30.41% 5.20% 5.07% -32.35%
Free Cash Flow Firm Growth		 1,223.88% -702.66% -22.70% 45.90% -103.36% -46.84% 115.56% -167.34% 12.03% -8.48% -1,855.65%
Invested Capital Growth		 206.61% 54.72% 733.91% -135.08% -19.10% 94.94% -89.57% 119.76% -89.60% 22,614.97% 2,094.69%
Revenue Q/Q Growth		 326.59% 31.38% 90.57% -91.88% 101.52% -538.81% 105.48% -27.60% 27.24% 26.06% -42.78%
EBITDA Q/Q Growth		 2,418.10% -213.17% 100.37% -31,542.18% 10.75% -29.76% 21.14% -10.82% -6.28% 216.05% -188.54%
EBIT Q/Q Growth		 2,358.73% -213.33% 98.73% -8,892.68% 19.70% -37.02% 20.81% -11.53% -6.71% 220.43% -186.05%
NOPAT Q/Q Growth		 3,509.75% -179.70% 47.10% -142.83% 19.70% 2.69% -6.71% -7.48% -10.75% 237.02% -178.76%
Net Income Q/Q Growth		 1,631.98% -209.00% 131.50% -586.91% 142.18% -313.74% -8.53% 39.38% -88.93% 213.40% -181.69%
EPS Q/Q Growth		 1,607.50% 0.00% 700.00% -358.33% 174.19% -221.74% -17.86% 48.48% -123.53% 189.47% -176.47%
Operating Cash Flow Q/Q Growth		 -7.14% 11.34% -77.79% -38.36% 22.32% 16.74% -18.44% 9.16% -5.83% 16.63% -65.12%
Free Cash Flow Firm Q/Q Growth		 2,908.35% -182.26% 16.13% 71.77% -74.26% -40.12% 120.79% -626.57% 42.66% -81.98% -219.51%
Invested Capital Q/Q Growth		 16.53% -142.29% 157.76% -113.33% 368.77% -102.65% 1,199.58% -74.75% 41.48% 5,631.64% 7.18%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 92.90% 100.00% 100.00% 106.11% 100.00%
EBITDA Margin		 33,012.75% -28,435.79% 1.95% -7,546.12% -3,342.17% 0.00% -14,213.00% -21,756.02% -18,172.04% 16,727.94% -25,881.69%
Operating Margin		 32,948.56% -28,428.39% -218.00% -7,636.04% -3,042.59% 0.00% -13,130.05% -19,492.87% -16,966.13% 16,477.78% -25,380.93%
EBIT Margin		 32,978.15% -28,445.80% -6.91% -7,654.32% -3,050.01% 0.00% -13,753.87% -21,189.43% -17,770.24% 16,976.67% -25,528.64%
Profit (Net Income) Margin		 32,596.49% -27,042.77% 104.28% -6,255.28% 1,309.33% 0.00% -12,622.63% -10,569.00% -15,692.90% 14,116.83% -20,152.98%
Tax Burden Percent		 98.43% 95.15% 81.96% 124.75% -50.35% 86.18% 101.73% 104.40% 108.04% 78.34% 98.66%
Interest Burden Percent		 100.42% 99.91% -1,841.56% 65.51% 85.26% 77.70% 90.22% 47.78% 81.74% 106.14% 80.02%
Effective Tax Rate		 0.43% 0.00% 18.04% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 21.66% 0.00%
Return on Invested Capital (ROIC)		 25,048.25% 0.00% -182.01% -24,849.16% -1,706.67% 0.00% -1,393.61% 0.00% -2,880.32% 361.47% -403.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 25,049.08% 0.00% -186.52% -24,847.97% -1,711.88% 0.00% -1,392.17% 0.00% -2,878.85% 360.86% -402.24%
Return on Net Nonoperating Assets (RNNOA)		 -24,539.55% 0.00% 178.50% 24,601.63% 1,680.48% 0.00% 1,352.34% 0.00% 2,848.79% -340.54% 374.81%
Return on Equity (ROE)		 508.70% 99.44% -3.51% -247.52% -26.19% -6.13% -41.26% -11.06% -31.53% 20.93% -28.19%
Cash Return on Invested Capital (CROIC)		 5,064.83% 0.00% 2,653.06% 0.00% -4,102.97% 0.00% -379.58% -11,626.31% -1,387.76% -161.29% -308.24%
Operating Return on Assets (OROA)		 431.24% -723.91% -0.25% -294.51% -41.46% 0.00% -55.43% -76.45% -42.93% 25.16% -37.20%
Return on Assets (ROA)		 426.25% -688.20% 3.82% -240.68% 17.80% 0.00% -50.87% -38.13% -37.92% 20.92% -29.36%
Return on Common Equity (ROCE)		 447.34% 89.11% -3.08% -218.70% -24.37% -5.62% -37.68% -10.13% -28.38% 18.40% -24.83%
Return on Equity Simple (ROE_SIMPLE)		 74.62% 0.00% 84.94% 90.58% -108.56% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 5,105 -4,069 -99 -239 -192 -187 -199 -214 -237 325 -256
NOPAT Margin		 32,805.57% -19,899.87% -178.67% -5,345.23% -2,129.81% 0.00% -9,191.03% -13,645.01% -11,876.29% 12,908.85% -17,766.65%
Net Nonoperating Expense Percent (NNEP)		 -0.83% -33.66% 4.51% -1.19% 5.21% -1.12% -1.43% 0.93% -1.47% 0.62% -0.76%
Return On Investment Capital (ROIC_SIMPLE)		 72.58% -63.10% - - -3.47% -3.60% -4.14% -4.46% -4.77% 6.15% -5.21%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 7.10% 0.00% 0.00% -6.11% 0.00%
SG&A Expenses to Revenue		 823.62% 1,113.02% 269.39% 4,533.65% 1,569.58% 0.00% 6,175.99% 9,110.44% 8,757.98% 6,279.76% 11,478.99%
R&D to Revenue		 694.95% 1,215.12% 241.62% 3,197.16% 1,570.14% 0.00% 7,046.96% 10,475.37% 8,273.14% 7,894.64% 14,009.43%
Operating Expenses to Revenue		 -32,848.56% 28,528.39% 318.00% 7,736.04% 3,142.59% 0.00% 13,222.95% 19,592.87% 17,066.13% -16,371.67% 25,480.93%
Earnings before Interest and Taxes (EBIT)		 5,132 -5,816 -3.81 -343 -275 -377 -298 -333 -355 428 -368
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 5,137 -5,814 1.07 -338 -301 -391 -308 -342 -363 422 -373
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.48 0.94 1.44 1.66 1.66 1.54 1.76 2.36 3.54 4.38 6.02
Price to Tangible Book Value (P/TBV)		 1.52 0.94 1.47 1.66 1.66 1.54 1.76 2.36 3.54 4.38 6.02
Price to Revenue (P/Rev)		 145.11 44.85 49.33 53.63 96.68 247.81 329.76 505.95 1,133.90 2,400.11 3,379.58
Price to Earnings (P/E)		 1.95 1.29 1.65 1.77 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 51.29% 77.70% 60.65% 56.36% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 24.91 0.00 9.55 0.00 35.42 0.00 115.57 811.50 1,047.80 26.81 34.41
Enterprise Value to Revenue (EV/Rev)		 49.20 0.00 16.74 20.51 39.54 86.38 143.96 291.72 813.92 1,923.75 2,902.13
Enterprise Value to EBITDA (EV/EBITDA)		 0.71 0.00 0.59 0.74 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.71 0.00 0.59 0.75 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.73 0.00 0.61 0.77 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.74 0.00 0.64 0.75 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.07 0.00 0.05 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.06 0.00 0.05 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.98 -1.02 -0.96 -0.99 -0.98 -1.00 -0.97 -1.00 -0.99 -0.94 -0.93
Leverage Ratio		 1.19 1.15 1.19 1.20 1.08 1.09 1.08 1.09 1.05 1.06 1.06
Compound Leverage Factor		 1.19 1.15 -21.99 0.78 0.92 0.85 0.97 0.52 0.86 1.13 0.85
Debt to Total Capital		 6.38% 0.00% 5.21% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.65% 0.00% 0.19% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 5.73% 0.00% 5.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 7.04% 7.44% 7.40% 7.65% 6.26% 9.63% 9.77% 9.22% 14.17% 14.46% 14.03%
Common Equity to Total Capital		 86.58% 92.56% 87.40% 92.35% 93.74% 90.37% 90.24% 90.78% 85.83% 85.54% 85.97%
Debt to EBITDA		 0.10 0.00 0.07 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 -1.49 0.00 -1.25 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.09 0.00 0.07 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.11 0.00 0.07 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 -1.53 0.00 -1.29 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.10 0.00 0.07 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 10.98 2.88 9.03 9.13 21.21 18.17 22.01 24.71 36.68 29.73 40.25
Noncontrolling Interest Sharing Ratio		 12.06% 10.39% 12.22% 11.65% 6.94% 8.42% 8.68% 8.38% 10.00% 12.07% 11.92%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 27.79 25.24 27.91 10.43 37.91 33.47 40.54 33.71 30.66 18.37 16.72
Quick Ratio		 27.24 24.35 26.41 9.68 36.38 32.71 39.55 32.77 29.81 15.26 13.55
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 5,022 -4,132 -343 -97 -169 -236 49 -259 -148 -270 -862
Operating Cash Flow to CapEx		 -59,282.25% -3.56% -19,982.28% -26,787.75% -11,343.79% -21,278.05% -5,065.25% -2,365.75% 0.00% -12,991.12% -64,559.43%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 -25.58 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 -14.39 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 -14.46 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.01 0.03 0.04 0.04 0.01 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 2.10 6.05 5.85 8.34 5.03 2.12 1.42 1.03 0.99 0.69 0.58
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 123 -52 278 -37 99 -2.63 29 7.31 10 593 635
Invested Capital Turnover		 0.76 -1.50 1.02 4.65 0.80 -1.06 0.15 -1.37 0.24 0.03 0.02
Increase / (Decrease) in Invested Capital		 83 63 244 -142 -23 49 -249 44 -89 595 606
Enterprise Value (EV)		 3,061 -666 2,650 3,263 3,522 2,509 3,345 5,930 10,833 15,890 21,859
Market Capitalization		 9,028 5,597 7,808 8,534 8,612 7,200 7,661 10,285 15,092 19,825 25,455
Book Value per Share		 $7.58 $7.41 $7.36 $6.97 $7.13 $6.57 $6.39 $6.41 $6.14 $6.33 $5.88
Tangible Book Value per Share		 $7.39 $7.41 $7.17 $6.97 $7.13 $6.57 $6.39 $6.41 $6.14 $6.33 $5.88
Total Capital		 7,034 6,449 6,219 5,580 5,536 5,187 4,816 4,805 4,974 5,292 4,922
Total Debt		 449 0.00 324 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 403 0.00 312 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -6,462 -6,743 -5,618 -5,698 -5,437 -5,190 -4,787 -4,798 -4,964 -4,700 -4,287
Capital Expenditures (CapEx)		 0.36 5,245 0.97 1.00 1.83 0.81 4.04 7.85 -4.94 1.26 0.42
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -63 -30 120 -142 76 -36 -1.27 -8.05 -22 594 616
Debt-free Net Working Capital (DFNWC)		 6,608 6,465 5,798 5,245 5,222 4,851 4,502 4,378 4,508 4,886 4,458
Net Working Capital (NWC)		 6,562 6,465 5,786 5,245 5,222 4,851 4,502 4,378 4,508 4,886 4,458
Net Nonoperating Expense (NNE)		 33 1,460 -156 41 -310 65 74 -48 76 -30 34
Net Nonoperating Obligations (NNO)		 -6,462 -6,501 -5,618 -5,617 -5,437 -5,190 -4,787 -4,798 -4,964 -4,700 -4,287
Total Depreciation and Amortization (D&A)		 5.39 2.05 4.88 4.84 -26 -14 -9.96 -8.90 -8.03 -6.27 -5.09
Debt-free, Cash-free Net Working Capital to Revenue		 -101.69% -23.95% 75.77% -89.10% 85.30% -124.73% -5.45% -39.58% -165.68% 7,195.00% 8,183.68%
Debt-free Net Working Capital to Revenue		 10,620.32% 5,180.55% 3,662.88% 3,295.97% 5,863.28% 16,695.88% 19,377.11% 21,534.70% 33,868.72% 59,154.24% 59,193.80%
Net Working Capital to Revenue		 10,546.86% 5,180.55% 3,655.30% 3,295.97% 5,863.28% 16,695.88% 19,377.11% 21,534.70% 33,868.72% 59,154.24% 59,193.80%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $6.37 ($7.01) $0.13 ($0.31) $0.23 ($0.29) ($0.33) ($0.17) ($0.38) $0.45 ($0.26)
Adjusted Weighted Average Basic Shares Outstanding		 800.59M 712.79M 735.82M 735.47M 722.72M 725.40M 680.29M 680.95M 696.86M 693.86M 720.78M
Adjusted Diluted Earnings per Share		 $6.03 ($6.67) $0.12 ($0.31) $0.23 ($0.28) ($0.33) ($0.17) ($0.38) $0.34 ($0.26)
Adjusted Weighted Average Diluted Shares Outstanding		 844.46M 712.79M 781.63M 735.47M 722.72M 725.40M 680.29M 680.95M 696.86M 693.86M 720.78M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 805.85M 738.72M 739.52M 727.95M 713.55M 679.81M 0.00 695.49M 715.70M 719.27M 722.32M
Normalized Net Operating Profit after Tax (NOPAT)		 -220 -325 -189 -239 -192 -187 -199 -214 -237 -278 -256
Normalized NOPAT Margin		 -1,413.68% -1,588.78% -342.77% -5,345.23% -2,129.81% 0.00% -9,191.03% -13,645.01% -11,876.29% -11,035.97% -17,785.68%
Pre Tax Income Margin		 33,116.21% -28,420.62% 127.23% -5,014.15% -2,600.50% 0.00% -12,408.39% -10,123.74% -14,525.71% 18,019.72% -20,427.46%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 -0.28 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 -7.35 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 -0.36 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 -7.42 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% -0.13% 0.11% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% -0.13% 0.11% -362.52% -123.98% -130.10% -50.07% -80.30% -76.69%

Financials Breakdown Chart

Key Financial Trends

Roivant Sciences’ latest quarter shows a company with a substantial liquidity cushion but continued operating losses. As of June 30, 2026, Roivant held $1.25 billion in cash and equivalents, $2.59 billion in short-term investments and $444.6 million in long-term investments. Combined, these assets totaled approximately $4.29 billion, or about 81% of total assets.

The balance sheet remains lightly levered. Total liabilities were just $384.6 million against $5.31 billion of assets, and the company reported no short-term or long-term debt in the latest statement. This produced a current ratio of roughly 16.7, providing meaningful financial flexibility. However, liquid assets have declined from the elevated levels reported in 2023 and 2024, while retained earnings have deteriorated to a deficit of $900.4 million.

Roivant’s operating business is not yet self-funding. Q1 2026 revenue was only $1.4 million, down from $2.5 million in the prior quarter and $2.2 million in the year-ago quarter. Against that revenue, the company incurred $165.5 million of selling, general and administrative expense and $202.0 million of research and development expense. The resulting operating loss was $366.0 million. Interest and investment income of $73.6 million reduced the net loss, but consolidated net loss still totaled $290.6 million, or $0.26 per share.

Cash flow trends remain a key concern. Operating cash flow was negative $270.5 million in Q1 2026, compared with negative $163.8 million in Q4 2025 and negative $204.4 million in Q1 2025. Roivant offset part of this burn through investment sales and maturities, which generated $568.2 million during the quarter. Financing cash flow was negative $181.5 million, primarily reflecting a $206.7 million share repurchase.

  • Large liquidity reserve: Cash, short-term investments and long-term investments totaled approximately $4.29 billion at the end of Q1 2026.
  • Low balance-sheet leverage: Total liabilities were only $384.6 million, with no reported short-term or long-term debt in the latest quarter.
  • Investment income provides support: Interest and investment income increased to $73.6 million in Q1 2026 from $26.3 million in Q4 2025, helping offset operating losses.
  • Investment portfolio remains liquid: Roivant sold or received maturities of $568.2 million of investments during Q1 while still reporting positive investing cash flow of $281.3 million.
  • Revenue remains limited and volatile: Quarterly revenue has generally stayed in the low-single-digit millions recently, making expense management and future product commercialization especially important.
  • Reported earnings are affected by unusual items: Q4 2025 included a $770.2 million favorable special item, which contributed to reported net income of $355.7 million. The return to a $290.6 million loss in Q1 2026 highlights the volatility of nonrecurring gains and charges.
  • Operating losses remain substantial: Q1 2026 operating expenses totaled $367.4 million against just $1.4 million of revenue, resulting in a $366.0 million operating loss.
  • Operating cash burn worsened: Cash flow from operating activities deteriorated to negative $270.5 million in Q1 2026 from negative $163.8 million in Q4 2025.
  • Accumulated losses are growing: Retained earnings declined to negative $900.4 million in Q1 2026 from negative $695.0 million in Q3 2025 and positive $671.5 million in Q1 2024.
  • Share count remains a dilution risk: Despite continued repurchases, weighted-average basic shares rose to approximately 720.8 million in Q1 2026 from 693.9 million in Q4 2025, which can reduce per-share benefits for existing investors.
08/20/26 12:09 PM ETAI Generated. May Contain Errors.

Roivant Sciences Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Roivant Sciences' fiscal year ends in March. Their fiscal year 2026 ended on March 31, 2026.

Roivant Sciences' net income appears to be on an upward trend, with a most recent value of -$397.91 million in 2025, falling from -$900.23 million in 2020. The previous period was -$356.73 million in 2024. Check out Roivant Sciences' forecast to explore projected trends and price targets.

Roivant Sciences' total operating income in 2025 was -$515.07 million, based on the following breakdown:
  • Total Gross Profit: $8.26 million
  • Total Operating Expenses: $523.33 million

Over the last 5 years, Roivant Sciences' total revenue changed from $23.80 million in 2020 to $8.26 million in 2025, a change of -65.3%.

Roivant Sciences' total liabilities were at $416.28 million at the end of 2025, a 66.7% increase from 2024, and a 21.1% decrease since 2020.

In the past 5 years, Roivant Sciences' cash and equivalents has ranged from $1.42 billion in 2025 to $6.49 billion in 2023, and is currently $1.42 billion as of their latest financial filing in 2025.

Over the last 5 years, Roivant Sciences' book value per share changed from 2.85 in 2020 to 6.33 in 2025, a change of 121.7%.


Related Companies

Financial statements for NASDAQ:ROIV last updated on 8/6/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
Someone just dumped the biggest gold fund.
Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...
Behind the Markets | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...
Paradigm Press | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Buffett's Final Warning: "The Dollar Is Going to Hell"
When Greece collapsed... the EU and IMF swooped in with $300 billion in bailouts. When America crosses that li...
Decentralized Masters | Sponsoredtc pixel
Pass by August 7… or wait until 2027?
And on June 29th, the Supreme Court quietly handed us one of the biggest privacy wins in decades, ruling the F...
Crypto 101 Media | Sponsoredtc pixel